Synvisc-One

Drug Overview

In the specialized field of Rheumatology, managing degenerative joint conditions requires a unique approach that differs from treating systemic autoimmune diseases. Synvisc-One is a premier medication within the Rheumatology category, classified specifically as a Viscosupplement. Unlike a systemic DMARD or an injectable Biologic that targets the entire immune system, Synvisc-One is a localized Targeted Therapy designed to treat the internal environment of a specific joint.

For patients living with the chronic pain of “wear-and-tear” arthritis, Synvisc-One serves as a high-tech supplement to the natural fluid found in healthy joints. It provides a non-surgical option for those who have found little relief from traditional small-molecule painkillers or physical therapy. This treatment is particularly valued for its ability to provide long-term relief with a single administration.

• Generic Name: Hylan G-F 20
• US Brand Names: Synvisc-One
• Route of Administration: Intra-articular injection (administered directly into the knee joint)
• FDA Approval Status: FDA-approved for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Synvisc-One works, one must first understand the physiology of a healthy joint. In a normal knee, a thick, slippery substance called synovial fluid acts as both a lubricant and a shock absorber. The key ingredient in this fluid is hyaluronan. In patients with osteoarthritis, the concentration and quality of this natural hyaluronan break down, leading to bone-on-bone friction and significant inflammation.

Getty Images

Synvisc-One is a Targeted Therapy that functions through a process called viscosupplementation. It is composed of Hylan G-F 20, a substance derived from hyaluronan that has been “cross-linked” to make it thicker and stay in the joint longer. Its mechanism involves several pathways:

1. Mechanical Lubrication: Upon injection, the Hylan G-F 20 molecules coat the surface of the articular cartilage. This reduces the coefficient of friction within the joint, allowing the bones to glide smoothly during movement.
2. Shock Absorption: Due to its high molecular weight, the medication acts as a viscous buffer. It absorbs the energy generated during impact activities like walking or climbing stairs, protecting the underlying bone from structural damage.
3. Biological Stimulation: Beyond simple lubrication, research shows that Synvisc-One interacts with synovial fibroblasts. It binds to specific CD44 receptors, which triggers the body’s own cells to produce more high-quality, natural hyaluronan.
4. Inhibition of Inflammatory Mediators: By reducing the mechanical friction, it helps suppress the production of pro-inflammatory cytokines and enzymes that contribute to the formation of a “synovial pannus-like” environment, which is common in advanced joint destruction.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Synvisc-One is the treatment of pain associated with Osteoarthritis (OA) of the knee. It is specifically indicated for patients who have not achieved satisfactory pain relief through low-impact exercise, weight loss, or the use of common Small Molecule medications like acetaminophen.

Other Approved & Off-Label Uses

While the primary FDA label is restricted to the knee, specialists in Rheumatology occasionally explore other uses:

• Osteoarthritis of the Hip or Shoulder: Used off-label in specialized clinical settings for patients with limited surgical options.
• Ankle Osteoarthritis: Emerging research suggests potential benefits in treating localized pain in the ankle joint.
• Note: Synvisc-One is not indicated for the treatment of systemic inflammatory conditions such as Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis, which generally require a systemic DMARD or Biologic therapy.

Primary Rheumatology Indications

• Knee Pain Management: Providing a mechanical and biological bridge to reduce dependency on steroid injections and chronic pain medications.
• Functional Improvement: Restoring the ability to perform activities of daily living by improving joint “glide” and reducing stiffness.
• Slowing Structural Progression: By optimizing joint mechanics, it helps preserve the remaining cartilage and prevents further joint destruction.

Dosage and Administration Protocols

Synvisc-One is unique because it is administered as a single-dose treatment. Because accuracy is vital to ensure the medication reaches the synovial space, these injections are performed by a specialist, often using ultrasound or fluoroscopic guidance.

Dose Adjustments

• Bilateral Treatment: If both knees are affected, they can be treated during the same visit using two separate single-dose syringes.
• Infection Presence: Injections must be postponed if there is an active skin infection or a severe “flare” with significant joint effusion (fluid buildup).
• Transition from Multi-Dose: Patients transitioning from the three-injection Synvisc regimen to the single-dose Synvisc-One do not require a specific wash-out period, provided the previous cycle was completed at least 6 months prior.

“Dosage must be individualized by a qualified healthcare professional.”

Getty Images

Clinical Efficacy and Research Results

Current clinical study data (2020–2026) reinforces Synvisc-One as a durable and efficacious option for knee pain. While systemic treatments for Rheumatoid Arthritis are measured by ACR20/50/70 scores, viscosupplements are evaluated using the WOMAC index (a measure of pain and function) and the Visual Analog Scale (VAS).

Numerical data from recent trials (2024) indicates that patients receiving Synvisc-One experience a significant reduction in pain that can last up to 26 weeks. In a large-scale meta-analysis, treated patients showed a 30% to 45% improvement in WOMAC function scores compared to those receiving saline placebos. While it is not a systemic DMARD, radiographic progression scores indicate that maintaining proper joint lubrication may slow the rate of joint space narrowing. This slowing of structural damage is vital for delaying the need for Total Knee Arthroplasty (TKA). Research has shown that patients using viscosupplementation can delay surgery by an average of 2.6 to 3.5 years compared to those using only conservative care.

Safety Profile and Side Effects

There is no Black Box Warning for Synvisc-One. It is generally considered one of the safest interventional treatments in Rheumatology because it is not a systemic drug.

Common side effects (>10%)

• Injection Site Pain: Temporary soreness or “fullness” at the needle entry point.
• Joint Swelling: Mild fluid buildup in the knee for 24–48 hours post-injection.
• Redness: Localized warmth or irritation of the skin over the knee.

Serious adverse events

• Septic Arthritis: A rare but serious infection of the joint space requiring immediate medical attention.
• Anaphylactoid Reactions: Very rare allergic reactions, particularly in patients with sensitivities to avian (bird) products, though modern purification has drastically reduced this risk.
• Pseudoseptic Reactions: An intense inflammatory flare within the joint that mimics an infection but is an acute sensitivity to the hylan molecules.

Management Strategies

To ensure safety, physicians use strict aseptic techniques. Patients are advised to rest the joint for 48 hours after the injection, avoiding strenuous activities like jogging or heavy lifting. Laboratory monitoring is not required for Synvisc-One, as it does not affect bone density or systemic organ function.

Research Areas

Direct Clinical Connections

Active research (2024–2026) is investigating the drug’s interaction with synovial fibroblasts and the RANKL pathway. Specialists are looking at whether long-term viscosupplementation can alter the “biological signature” of the joint to favor cartilage preservation over bone remodeling.

Generalization and Systemic Involvement

In the absence of a “Biosimilar” category for medical devices, research is currently focused on Novel Delivery Systems. This includes hydrogel-based hyaluronan that releases the medication even more slowly. Research is also documenting the drug’s efficacy in preventing extra-articular manifestations of OA, such as hip or lower back pain caused by an altered walking gait.

Severe Disease

Research continues to validate Synvisc-One’s role in “Precision Rheumatology,” identifying which patients (based on baseline joint X-rays) will respond best to the 6 mL dose.

Disclaimer: The content provided is for informational use and does not constitute medical advice. Please consult with a qualified healthcare professional to discuss specific clinical applications, risks, or therapeutic alternatives. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Weight-bearing Joint X-rays (Kellgren-Lawrence scale) and Health Assessment Questionnaire (HAQ-DI) to assess physical function.
• Organ Function: No specific renal or hepatic monitoring is required, unlike common DMARD therapy.
• Specialized Testing: Ultrasound to check for joint effusion. Rheumatoid Factor (RF) and ANA titers may be checked to rule out systemic autoimmune conditions.

Monitoring and Precautions

• Vigilance: Monitoring for “flares” versus medication failure and tracking laboratory markers of inflammation (CRP/ESR) if the patient has a secondary inflammatory condition.
• Lifestyle:
  • Low-impact exercise: Swimming or cycling is strongly encouraged to help “pump” the medication through the joint.
  • Joint Protection: Instruction on using proper footwear and unloader braces.
  • Smoking Cessation: Critical for joint health and general tissue healing.

“Do’s and Don’ts” list

• DO keep the injection site clean and dry for 24 hours.
• DO move your knee gently after the injection to help distribute the fluid.
• DO report any fever or severe, worsening redness immediately.
• DON’T engage in high-impact sports (tennis, running) for 48 hours post-injection.
• DON’T expect “instant” relief; the benefits typically build over several weeks.
• DON’T ignore signs of a “pseudoseptic” flare (sudden, extreme pain/swelling).

Legal Disclaimer

This guide is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified specialist in Rheumatology or your primary care physician with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. Synvisc-One is an intra-articular therapy and must be administered by a licensed healthcare professional.